Holen Sie sich die Stockscreener-App
2.24
0.22%
0.005
Handel nachbörslich:
2.24
Schlusskurs vom Vortag:
$2.235
Offen:
$2.25
24-Stunden-Volumen:
235.30K
Relative Volume:
0.51
Marktkapitalisierung:
$161.99M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-113.28M
KGV:
-1.2071
EPS:
-1.8557
Netto-Cashflow:
$-105.55M
1W Leistung:
-15.47%
1M Leistung:
-27.74%
6M Leistung:
-14.83%
1J Leistung:
+51.35%
1-Tages-Spanne:
$2.22
$2.295
1-Wochen-Bereich:
$2.22
$2.705
52-Wochen-Spanne:
$1.42
$3.60
Acumen Pharmaceuticals Inc Stock (ABOS) Company Profile
Firmenname
Acumen Pharmaceuticals Inc
Sektor
Branche
Telefon
617-344-4190
Adresse
1210-1220 WASHINGTON STREET, NEWTON
Compare ABOS vs VRTX, REGN, MRNA, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABOS
Acumen Pharmaceuticals Inc
|
2.24 | 161.99M | 0 | -113.28M | -105.55M | -1.8557 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Acumen Pharmaceuticals Inc Stock (ABOS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-17 | Eingeleitet | Citigroup | Buy |
| 2024-07-26 | Eingeleitet | Citigroup | Buy |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-07-20 | Fortgesetzt | BofA Securities | Buy |
| 2023-05-18 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-07-15 | Eingeleitet | BTIG Research | Buy |
| 2022-06-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-01-21 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-07-26 | Eingeleitet | BofA Securities | Neutral |
| 2021-07-26 | Eingeleitet | Credit Suisse | Outperform |
| 2021-07-26 | Eingeleitet | Stifel | Buy |
| 2021-07-26 | Eingeleitet | UBS | Buy |
Alle ansehen
Acumen Pharmaceuticals Inc Aktie (ABOS) Neueste Nachrichten
ABOS Should I Buy - intellectia.ai
Analysts’ Top Healthcare Picks: Acumen Pharmaceuticals (ABOS), High Tide (HITI) - The Globe and Mail
BTIG Maintains Acumen Pharmaceuticals(ABOS.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Acumen Pharmaceuticals (NASDAQ: ABOS) Aims for Late 2026 Sabirnetug Phase 2 Topline Data - Kalkine Media
Form 8K Acumen Pharmaceuticals Inc For: 16 September By Investing.com - Investing.com South Africa
BTIG reiterates Buy rating on Acumen Pharmaceuticals, $8 price target - tradingview.com
Acumen Pharmaceuticals, Inc. (ABOS) Analyst/Investor DaySlideshow (NASDAQ:ABOS) 2026-09-16 - Seeking Alpha
Acumen Pharmaceuticals to Webcast Investor Day; ALTITUDE-AD topline expected late 2026, EBD IND targeted mid-2027 - TradingView
Citi Maintains Acumen Pharmaceuticals(ABOS.US) With Buy Rating, Raises Target Price to $5 - Moomoo
Acumen Pharmaceuticals to host virtual investor day focusing on AβO therapies and ALTITUDE-AD study - Traders Union
Acumen Pharmaceuticals to Hold Virtual Investor Day on September 16, 2026 - manilatimes.net
Acumen will meet investors online Sept. 16 - Stock Titan
Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences - Moomoo
An Alzheimer’s drug developer will join two live online events Sept. 9 and 10 - Stock Titan
Acumen Pharmaceuticals to Present Data on Enhanced Brain Delivery™ (EBD™) Technology and Early Alzheimer’s Disease Insights at the Alzheimer’s Association International Conference (AAIC®) 2026 - Barchart.com
Acumen Pharmaceuticals Earnings Call: Science vs. Runway - TipRanks
Acumen (ABOS) Trading: Finishes 0.94% Lower at $3.16 on the Day; Price Setup: the Session Ends Within the Reported Technical Boundaries under the Current SnapshotRegression Channel - dars.gov.et
Acumen Pharmaceuticals Inc (ABOS) Stock News Today - TradingKey
Acumen Pharmaceuticals (ABOS) Advances 4.7% to $2.67 as Momentum BuildsForce Index - vinanet.vn
Conferencia de resultados del T2 de 2026 de Acumen Pharmaceuticals (ABOS): lectura de datos de ALTITUDE-AD prevista para finales de 2026 - TradingKey
Acumen Pharmaceuticals (ABOS) Edges Higher: Biotech Stock Gains 1.59% as Bulls Target $2.68 ResistanceCall Wall - vinanet.vn
Citi Maintains Acumen Pharmaceuticals(ABOS.US) With Buy Rating, Maintains Target Price $4 - moomoo.com
Acumen Pharmaceuticals (NASDAQ:ABOS) Releases Quarterly Earnings Results, Misses Estimates By $0.09 EPS - MarketBeat
Acumen Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Acumen Pharmaceuticals Q2 EPS $(0.45) misses $(0.34) estimate - scanx.trade
Acumen Pharmaceuticals, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:ABOS) 2026-08-12 - Seeking Alpha
ABOS: Phase II Alzheimer's trial on track for late 2026 readout; strong cash position supports pipeline - TradingView
Acumen Pharmaceuticals Q2 Earnings Call Highlights - MarketBeat
ABOS: Phase II Alzheimer's trial on track for late 2026 readout; strong cash position and pipeline progress - TradingView
Second quarter earnings and operational progress released by Acumen Pharmaceuticals, Inc. - Traders Union
Acumen Pharmaceuticals Q2 2026 Earnings Call Transcript - MarketBeat
Acumen Pharmaceuticals Reports Q2 Results, Advances Alzheimer’s Programs - TipRanks
Form 8K Acumen Pharmaceuticals Inc For: 12 August By Investing.com - Investing.com Australia
Acumen Pharmaceuticals Reports Second-Quarter 2026 Results and Advances Alzheimer’s Pipeline, with ALTITUDE-AD Topline Data Expected in Late 2026 - Quiver Quantitative
Acumen Pharmaceuticals Q2 net loss widens, misses analyst estimates - TradingView
Acumen Reports Q2 Net Loss as Alzheimer’s Trial Readout Nears - Quiver Quantitative
Acumen Pharmaceuticals Inc (ABOS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Acumen Pharmaceuticals Inc expected to post a loss of 37 cents a shareEarnings Preview - TradingView
Acumen Pharmaceuticals, Inc. (ABOS) stock price, news, quote and history - Yahoo Finance Australia
Acumen Pharmaceuticals (ABOS.US) will release its earnings report before the market opens on August 12. - Moomoo
Acumen Pharmaceuticals to Report Second Quarter Financial Results on August 12, 2026 - manilatimes.net
Enterprise value to EBITDA forward of Acumen Pharmaceuticals, Inc. – NASDAQ:ABOS - TradingView
Alzheimer’s drug developer Acumen sets Aug. 12 webcast at 8 a.m. - Stock Titan
Price to book forward of Acumen Pharmaceuticals, Inc. – NASDAQ:ABOS - TradingView
Acumen Pharmaceuticals (ABOS) Holds Steady at $2.24 as Key Support and Resistance Levels Come Into FocusVWAP Bounce - careplusvn.com
Acumen Pharmaceuticals (ABOS) Projected to Release Earnings on Tuesday - MarketBeat
Is Acumen Pharmaceuticals (ABOS) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Acumen Pharmaceuticals Inc - TradingKey
ABOS|Acumen Pharmaceuticals Inc|Price:2.235|Chg%:+0.105 - TradingKey
ABOS|Acumen Pharmaceuticals Inc|Price:2.440|Chg%:+0.160 - TradingKey
Price to earnings forward of Acumen Pharmaceuticals, Inc. – NASDAQ:ABOS - TradingView
Finanzdaten der Acumen Pharmaceuticals Inc-Aktie (ABOS)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.06%
2.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):